Merger between AstraZeneca and Gilead science

AstraZeneca and Gilead are both the world known pharmaceutical brands who are leading with

innovations in the medicine industry and treating millions of patients worldwide. Both of the

brands are dealing research and development areas to discover the most of the innovations in the

medicines yet these both brands played the biggest role in research and development in the

pandemic times when there is rush of the Corona virus in the world.

Recently, the world known pharmaceutical brand AstraZeneca offer the Gilead pharmaceutical

brand for the biggest merger saying that it could be the biggest health care merger in fighting

against Corona virus or fighting against any other diseases treatments. Both the brands are

successfully producing 2million doses every month to treat Corona patients who are severely

affected by the world pandemic Corona. Both companies AstraZeneca and Gilead had their

shares down in the market before the pandemic but as they started developing and research on

the pandemic Corona AstraZeneca’s shares increased by 3% and the Gilead’s shares increased

by 15% and this is the biggest difference between both the companies as Gilead has plenty of

cash as compared to the AstraZeneca and this is the main potential difference and the main

potential turn for both companies as they would involve in this merger.

Furthermore, the company AstraZeneca did not specify any financial involvement in this deal but

the other company Gilead took interest in this deal and had a meeting to discuss the financial

stability, pros and cons and other important terms in the meeting but did not reach at the

conclusion to response AstraZeneca’s offer. Both the companies AstraZeneca and Gilead have

the stock market shares worth of $140 billion. But Gilead company holds more cash and

AstraZeneca is interested in the cash for the dividends payments if Gilead agrees to this merger.